Haddad, Tufia C. http://orcid.org/0000-0001-8226-3581
He, Jun
O’Sullivan, Ciara C.
Chen, Beiyun
Northfelt, Donald
Dueck, Amylou C.
Ballman, Karla V.
Tenner, Kathleen S.
Linden, Hannah
Sparano, Joseph A.
Hopkins, Judith O.
De Silva, Chamath
Perez, Edith A.
Haluska, Paul
Goetz, Matthew P.
Funding for this research was provided by:
Foundation for the National Institutes of Health (U10CA180821, U10CA180882, UG1CA232760, U10CA180820, UG1CA189859, U10CA180868, UG1CA189821, U10CA180888)
Article History
Received: 28 January 2021
Accepted: 30 March 2021
First Online: 14 April 2021
Declarations
:
: Jun He, Beiyun Chen, Donald Northfelt, Amylou C. Dueck, Karla V. Ballman, Kathleen S. Tenner, Hannah Linden, Joseph A. Sparano<sup>6</sup>, Judith O. Hopkins<sup>7</sup>, Chamath De Silva, Edith A. Perez. Ciara C. O’Sullivan declares research funding to institution (Mayo) from the following companies: Lilly, Seattle Genetics, Bavarian Nordic, Minnemarita Therapeutics, and Biovica. Matthew P. Goetz declares funding acknowledgement to named Professorship: Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D., and consulting fees to institution from Eagle Pharmaceuticals, Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics, and grant funding to institution from Pfizer, Sermonix, and Lilly. Paul Haluska discloses he is a current employee and stockholder of Bristol Myers Squibb. Tufia C. Haddad declares grant funding to the Mayo Clinic from Takeda Oncology.
: Each participant signed an IRB-approved, protocol-specific informed consent document in accordance with federal and institutional guidelines.
: Patients signed informed consent regarding publishing their data.
: The study was conducted in accordance with the Declaration of Helsinki, and this phase <i>II</i> therapeutic trial was monitored at least twice annually by the Data and Safety Monitoring Board, a standing committee composed of individuals from within and outside of the Alliance.